Prognostic comparison between implantable cardioverter-defibrillator and amiodarone in cancer patients.

ABSTRACT:

Background

Implantable cardioverter-defibrillator (ICD) has been demonstrated to improve survival outcomes compared to amiodarone. However, this effectiveness in cancer patients remains unclear. Given the complexity of cardiovascular management in this population, including cancer stage considerations, we evaluated the relative effectiveness of ICD versus amiodarone in cancer patients.

Methods and results

We linked cancer registry data with administrative records to identify patients newly prescribed amiodarone or who underwent ICD implantation between 2010 and 2015 at 36 hospitals in Osaka Prefecture, Japan. Among 161,125 cancer patients, 339 met the inclusion criteria (amiodarone: n = 281; ICD: n = 58), with a median follow-up of 762 days. Kaplan-Meier analys

SUBMITTER: Kida H 

PROVIDER: S-EPMC12086514 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature